Health
ImmunityBio Announces Novel ACE2 Decoy COVID-19 Therapeutic that Shows High Binding to SARS-CoV-2 Variants and Neutralizes Live Viruses – Business Wire
ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine
CULVER CITY, Calif.–(BUSINESS WIRE)–ImmunityBio, Inc. (NASDAQ: IBRX), a clinical-stage immunotherapy company, today announced it is developing a novel hAd5 ACE2 Decoy therapeutic vaccine to neutralize the SARS-CoV-2 virus, including the E484K and N501Y mutations. The company presented the results in an oral presentation at the 28th Conference on Retroviruses and Opportunistic Infections (CROI) and published the positive findings of high binding affinity to the variants in preprint server, bioRxiv…
-
Noosa News19 hours agoMega-team of heavy horses sets world record at Good Old Days Festival
-
General23 hours agoEnglish springer spaniels Kelly and Milo helping fight dieback in Western Australia
-
General22 hours agoHomicide Squad investigating ‘suspicious’ death of 84yo woman in Sydney suburb of Melonba
-
Noosa News12 hours agoNRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership